View More 2022, Scientific Sessions, Session Coverage

Scientific Sessions return to the road for five days of cutting-edge basic, translational, and clinical science


Estimated Read Time:

4 minutes

Dana Dabelea, MD, PhD
Dana Dabelea, MD, PhD

The 82nd Scientific Sessions are headed to New Orleans, June 3-7 at the Ernest N. Morial Convention Center, with a dynamic program featuring more than 180 sessions and over 1,000 original abstract presentations covering the hottest topics, trials, and trends in diabetes research, prevention, and care.

“After two years of fully virtual meetings, we are so excited to be back together in New Orleans this year,” said Dana Dabelea, MD, PhD, Chair of the 82nd Scientific Sessions Meeting Planning Committee. “We’ve put together an incredibly rich program with everything you have come to expect from the world’s largest scientific meeting focused on the management and care of the millions of people worldwide living with diabetes.”

The Scientific Sessions program encompasses eight major theme areas and each day of the meeting will include up to 14 concurrent sessions presented live in New Orleans, as well as four concurrent livestreams of featured presentations for those unable to attend the meeting in person. The rest of the program will be available on demand for both in-person and virtual attendees.

Scientific Sessions Theme Areas

  • Acute and Chronic Complications
  • Behavioral Medicine, Clinical Nutrition, Education, and Exercise
  • Clinical Diabetes/Therapeutics
  • Epidemiology/Genetics
  • Immunology/Transplantation
  • Insulin Action/Molecular Metabolism
  • Integrated Physiology/Obesity
  • Islet Biology/Insulin Secretion

“An overarching theme of the meeting is the growing epidemic of diabetes. Among the many sessions that address this, we have a very important symposium on the recent National Clinical Care Commission report to Congress on diabetes prevention and control in the U.S.,” Dr. Dabelea said. “This is important because the last report was done all the way back in 1975. Since then, this country has seen an explosion in the numbers of people diagnosed with diabetes, affecting many families, many communities, and increasing health care costs tremendously. This report really makes the case and contains evidence-based recommendations for preventing type 2 diabetes in the general population, as well as in high-risk populations.”

The program also includes a special symposium summarizing key updates and highlights from the ADA’s recently published 2022 Standards of Medical Care in Diabetes, as well as numerous sessions focusing on health disparities and health equity in diabetes.

“And then, of course, we’ll hear all of the latest developments and trial results on novel therapies for type 2 diabetes, such as the next wave of incretin therapies, and important new information on the role of GLP-1 dual agonists in the treatment of diabetes, cardiovascular risk reduction, management of chronic kidney disease, and treatment of obesity,” Dr. Dabelea said. “We also have some in-depth sessions focused on breakthroughs in type 1 diabetes prevention and treatment, including results of new type 1 diabetes intervention trials from TrialNet and much-awaited results from the randomized Insulin-Only Bionic Pancreas Pivotal Trial.”

Dr. Dabelea recommended several high-profile sessions below. View the Advance Program for more in-depth session information, including detailed speaker, topic, and schedule information.

  • ADA Standards of Care 2022 Spotlight—Prevention or Delay of Type 2 Diabetes and Associated Comorbidities
  • A Transformative Approach to the Prevention and Control of Diabetes in the U.S—The National Clinical Care Commission 2022 Report to Congress
  • NIDDK Early Career Investigator Symposium: Novel Diabetes Prevention and Treatment Approaches in Underserved Populations
  • Type 1 Diabetes Intervention Trials: TrialNet Abatacept Prevention Trial & Low-dose IL-2 in Recently Diagnosed Type 1 Diabetes
  • The Year in Review—Highlights of the Past Year in Basic, Translational, and Clinical Science
  • Future of Diabetes—The Next Frontier with Dual Incretin

Scientific Sessions registration should be completed via the ADA’s secure online registration portal, which features special pricing for three categories of attendees: ADA members, non-members, and students/residents/fellows. Advance Registration rates are available until April 21.

To promote the health and well-being of all Scientific Sessions participants in New Orleans, the ADA will require all attendees, exhibitors, staff, and vendors to be fully vaccinated against COVID-19 prior to entering the Ernest N. Morial Convention Center, in accordance with applicable law. For purposes of its protocols, the ADA is utilizing the Centers for Disease and Prevention Control’s definition of “fully vaccinated” on the CDC website.